Radiotheranostics refers to dual diagnostic–therapeutic capacity that allows for precision medicine at an unprecedented level, reducing collateral toxicity and improving patient outcomes ([1][1]). In ...

Journal of Nuclear Medicine September 2025, jnumed.125.269636; DOI: https://doi.org/10.2967/jnumed.125.269636 ...

Journal of Nuclear Medicine September 2025, jnumed.125.270358; DOI: https://doi.org/10.2967/jnumed.125.270358 ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. After the use of liver-directed therapies, it is challenging to differentiate between nonviable tumor and ...

Journal of Nuclear Medicine August 2025, jnumed.124.269234; DOI: https://doi.org/10.2967/jnumed.124.269234 ...

Journal of Nuclear Medicine July 2025, jnumed.125.270167; DOI: https://doi.org/10.2967/jnumed.125.270167 ...

Journal of Nuclear Medicine July 2025, jnumed.125.269729; DOI: https://doi.org/10.2967/jnumed.125.269729 ...

Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We ...

Results: The patients underwent 1-2 cycles of TANDEM PRLT with 177 Lu (5.05 ± 1.09 GBq) and 225 Ac (6.87 ± 3.14 MBq) per cycle, receiving 16 BTX treatments. All patients were heavily pre-treated, with ...

Journal of Nuclear Medicine June 2025, 66 (supplement 1) 252173; ...

Journal of Nuclear Medicine May 2025, jnumed.125.269519; DOI: https://doi.org/10.2967/jnumed.125.269519 ...

Journal of Nuclear Medicine April 2025, jnumed.124.269064; DOI: https://doi.org/10.2967/jnumed.124.269064 ...